The life cycle of hepatitis B virus and antiviral targets

Future Virology

Volumn 6, Issue 5, 2011, Pages 599-614

  Lucifora, Julie ^a   Zoulim, Fabien ^b,c,d,e  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

^c UNIVERSITÉ DE LYON   (France)

^d HOSPICES CIVILS DE LYON   (France)

^e INSTITUT UNIVERSITAIRE DE FRANCE   (France)

Author keywords

antiviral targets; hepatitis B virus; inhibitory drugs; life cycle

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; BOEHMERIA NIVEA EXTRACT; CAPSID PROTEIN; CIRCULAR DNA; COMPLEMENTARY DNA; CURCUMA LONGA EXTRACT; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; HYPERICIN; PHYLLANTHUS AMARUS EXTRACT; PLANT EXTRACT; RECOMBINANT ALPHA INTERFERON; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN;

DNA DAMAGE; DNA REPAIR; DNA STRAND; DNA SYNTHESIS; ENDOSOME; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INNATE IMMUNITY; LIFE CYCLE; LIVER CELL; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE; RNA TRANSCRIPTION; TREATMENT OUTCOME; VIRION; VIRUS ASSEMBLY; VIRUS CAPSID; VIRUS CELL INTERACTION; VIRUS ENTRY; VIRUS GENOME; VIRUS INFECTIVITY; VIRUS LOAD; VIRUS MORPHOGENESIS; VIRUS RELEASE; VIRUS REPLICATION;

HEPATITIS B VIRUS;

EID: 79957606295     PISSN: 17460794     EISSN: 17460808     Source Type: Journal    
DOI: 10.2217/fvl.11.29     Document Type: Review

References (145)

1. Karayiannis P: Hepatitis B virus: old, new and future approaches to antiviral treatment. J. Antimicrob. Chemother. 51(4), 761-785 (2003). (Pubitemid 36503410)
2. Liaw YF, Sung JJ, Chow WC et al.: Lamivudine for patients with chronic hepatitis B and advanced liver disease. N. Engl. J. Med. 351(15), 1521-1531 (2004).
3. Zoulim F, Lucifora J: Hepatitis B virus and drug resistance: implications for treatment. Future Virol. 1, 361-376 (2006).
4. Bertoletti A, Gehring AJ: The immune response during hepatitis B virus infection. J. Gen. Virol. 87(Pt 6), 1439-1449 (2006). (Pubitemid 43827198)
5. Chen MT, Billaud JN, Sallberg M et al.: A function of the hepatitis B virus precore protein is to regulate the immune response to the core antigen. Proc. Natl Acad. Sci. USA 101(41), 14913-14918 (2004). (Pubitemid 39410774)
6. Chen M, Sallberg M, Hughes J et al.: Immune tolerance split between hepatitis B virus precore and core proteins. J. Virol. 79(5), 3016-3027 (2005). (Pubitemid 40270581)
7. Visvanathan K, Skinner NA, Thompson AJ et al.: Regulation of Toll-like receptor-2 expression in chronic hepatitis B by the precore protein. Hepatology 45(1), 102-110 (2007). (Pubitemid 46150869)
8. Murakami S: Hepatitis B virus X protein: a multifunctional viral regulator. J. Gastroenterol. 36(10), 651-660 (2001). (Pubitemid 33040937)
9. Bouchard MJ, Schneider RJ: The enigmatic X gene of hepatitis B virus. J. Virol. 78(23), 12725-12734 (2004). (Pubitemid 39507781)
10. Lucifora J, Arzberger S, Durantel D et al.: Hepatitis B virus X protein is essential to initiate and maintain virus replication after infection. J. Hepatol. DOI: 10.1016/j. jhep.2011.02.015 (2011) (In Press).
11. Kott N, König A, Glebe D: Hepatitis B virus (HBV) bypasses classical endocytic pathways to infect primary hepatocytes in vitro. J. Hepatol. 52(Suppl. 1), S48-S49 (2010).
12. Stoeckl L, Funk A, Kopitzki A et al.: Identification of a structural motif crucial for infectivity of hepatitis B viruses. Proc. Natl Acad. Sci. USA 103(17), 6730-6734 (2006).
13. Rabe B, Glebe D, Kann M: Lipid-mediated introduction of hepatitis B virus capsids into nonsusceptible cells allows highly efficient replication and facilitates the study of early infection events. J. Virol. 80(11), 5465-5473 (2006).
14. Seeger C, Mason B, Zoulim F: Hepadnaviruses. In: Fields Virology. Knipe DM, Howley PM (Eds). Lippincott Williams and Wilkins, PA, USA 2977-3029 (2006).
15. Gripon P, Rumin S, Urban S et al.: Infection of a human hepatoma cell line by hepatitis B virus. Proc. Natl Acad. Sci. USA 99(24), 15655-15660 (2002). (Pubitemid 35403987)
16. Kock J, Nassal M, Macnelly S, Baumert TF, Blum HE, Von Weizsacker F: Efficient infection of primary tupaia hepatocytes with purified human and woolly monkey hepatitis B virus. J. Virol. 75(11), 5084-5089 (2001). (Pubitemid 32448530)
17. Dandri M, Burda MR, Torok E et al.: Repopulation of mouse liver with human hepatocytes and in vivo infection with hepatitis B virus. Hepatology 33(4), 981-988 (2001). (Pubitemid 32246649)
18. Bruss V, Lu X, Thomssen R, Gerlich WH: Post-translational alterations in transmembrane topology of the hepatitis B virus large envelope protein. EMBO J. 13(10), 2273-2279 (1994). (Pubitemid 24157601)
19. Neurath AR, Kent SB, Strick N, Parker K: Identification and chemical synthesis of a host cell receptor binding site on hepatitis B virus. Cell 46(3), 429-436 (1986). (Pubitemid 16031679)
20. Petit MA, Dubanchet S, Capel F, Voet P, Dauguet C, Hauser P: HepG2 cell binding activities of different hepatitis B virus isolates: inhibitory effect of anti-HBs and antipreS1( 21-47). Virology 180(2), 483-491 (1991).
21. Glebe D, Urban S, Knoop EV et al.: Mapping of the hepatitis B virus attachment site by use of infection-inhibiting preS1 lipopeptides and tupaia hepatocytes. Gastroenterology 129(1), 234-245 (2005). (Pubitemid 41002057)
22. Gripon P, Le Seyec J, Rumin S, Guguen-Guillouzo C: Myristylation of the hepatitis B virus large surface protein is essential for viral infectivity. Virology 213(2), 292-299 (1995).
23. Bruss V, Hagelstein J, Gerhardt E, Galle PR: Myristylation of the large surface protein is required for hepatitis B virus in vitro infectivity. Virology 218(2), 396-399 (1996). (Pubitemid 26164741)
24. Gripon P, Cannie I, Urban S: Efficient inhibition of hepatitis B virus infection by acylated peptides derived from the large viral surface protein. J. Virol. 79(3), 1613-1622 (2005). (Pubitemid 40459108)
25. Petersen J, Dandri M, Mier W et al.: Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. Nat. Biotechnol. 26(3), 335-341 (2008). (Pubitemid 351355128)
26. Chai N, Gudima S, Chang J, Taylor J: Immunoadhesins containing pre-S domains of hepatitis B virus large envelope protein are secreted and inhibit virus infection. J. Virol. 81(10), 4912-4918 (2007). (Pubitemid 46744402)
27. Schulze A, Gripon P, Urban S: Hepatitis B virus infection initiates with a large surface protein-dependent binding to heparan sulfate proteoglycans. Hepatology 46(6), 1759-1768 (2007).
28. Leistner CM, Gruen-Bernhard S, Glebe D: Role of glycosaminoglycans for binding and infection of hepatitis B virus. Cell Microbiol. 10(1), 122-133 (2008). (Pubitemid 350239061)
29. Neurath AR, Strick N: Antigenic mimicry of an immunoglobulin A epitope by a hepatitis B virus cell attachment site. Virology 178(2), 631-634 (1990). (Pubitemid 20349908)
30. Pontisso P, Ruvoletto MG, Tiribelli C, Gerlich WH, Ruol A, Alberti A: The preS1 domain of hepatitis B virus and IgA cross-react in their binding to the hepatocyte surface. J. Gen. Virol. 73(Pt 8), 2041-2045 (1992).
31. Dash S, Rao KV, Panda SK: Receptor for pre-S1(21-47) component of hepatitis B virus on the liver cell: role in virus cell interaction. J. Med. Virol. 37(2), 116-121 (1992).
32. Neurath AR, Strick N, Sproul P: Search for hepatitis B virus cell receptors reveals binding sites for interleukin 6 on the virus envelope protein. J. Exp. Med. 175(2), 461-469 (1992).
33. Neurath AR, Strick N, Li YY: Cells transfected with human interleukin 6 cDNA acquire binding sites for the hepatitis B virus envelope protein. J. Exp. Med. 176(6), 1561-1569 (1992).
34. Petit MA, Capel F, Dubanchet S, Mabit H: PreS1-specific binding proteins as potential receptors for hepatitis B virus in human hepatocytes. Virology 187(1), 211-222 (1992).
35. Treichel U, Meyer Zum Buschenfelde KH, Stockert RJ, Poralla T, Gerken G: The asialoglycoprotein receptor mediates hepatic binding and uptake of natural hepatitis B virus particles derived from viraemic carriers. J. Gen. Virol. 75(Pt 11), 3021-3029 (1994). (Pubitemid 24340855)
36. Mehdi H, Kaplan MJ, Anlar FY et al.: Hepatitis B virus surface antigen binds to apolipoprotein H. J. Virol. 68(4), 2415-2424 (1994). (Pubitemid 24091921)
37. Treichel U, Meyer Zum Buschenfelde KH, Dienes HP, Gerken G: Receptor-mediated entry of hepatitis B virus particles into liver cells. Arch. Virol. 142(3), 493-498 (1997). (Pubitemid 27161769)
38. Duclos-Vallee JC, Capel F, Mabit H, Petit MA: Phosphorylation of the hepatitis B virus core protein by glyceraldehyde-3-phosphate dehydrogenase protein kinase activity. J. Gen. Virol. 79(Pt 7), 1665-1670 (1998). (Pubitemid 28330670)
39. Ryu CJ, Cho DY, Gripon P et al.: An 80-kilodalton protein that binds to the pre-S1 domain of hepatitis B virus. J. Virol. 74(1), 110-116 (2000). (Pubitemid 30002889)
40. Stefas I, Rucheton M, D'Angeac AD et al.: Hepatitis B virus Dane particles bind to human plasma apolipoprotein H. Hepatology 33(1), 207-217 (2001). (Pubitemid 32016904)
41. Owada T, Matsubayashi K, Sakata H et al.: Interaction between desialylated hepatitis B virus and asialoglycoprotein receptor on hepatocytes may be indispensable for viral binding and entry. J. Viral Hepat. 13(1), 11-18 (2006).
42. Deng Q, Zhai JW, Michel ML et al.: Identification and characterization of peptides that interact with hepatitis B virus via the putative receptor binding site. J. Virol. 81(8), 4244-4254 (2007). (Pubitemid 46586918)
43. Kann M, Sodeik B, Vlachou A, Gerlich WH, Helenius A: Phosphorylation- dependent binding of hepatitis B virus core particles to the nuclear pore complex. J. Cell Biol. 145(1), 45-55 (1999). (Pubitemid 29177674)
44. Rabe B, Vlachou A, Pante N, Helenius A, Kann M: Nuclear import of hepatitis B virus capsids and release of the viral genome. Proc. Natl Acad. Sci. USA 100(17), 9849-9854 (2003). (Pubitemid 37087030)
45. Rabe B, Delaleau M, Bischof A et al.: Nuclear entry of hepatitis B virus capsids involves disintegration to protein dimers followed by nuclear reassociation to capsids. PLoS Pathog. 5(8), E1000563 (2009).
46. Schmitz A, Schwarz A, Foss M et al.: Nucleoporin 153 arrests the nuclear import of hepatitis B virus capsids in the nuclear basket. PLoS Pathog. 6(1), e1000741 (2010).
47. Gao W, Hu J: Formation of hepatitis B virus covalently closed circular DNA: removal of genome-linked protein. J. Virol. 81(12), 6164-6174 (2007). (Pubitemid 46878023)
48. Guo H, Jiang D, Zhou T, Cuconati A, Block TM, Guo JT: Characterization of the intracellular deproteinized relaxed circular DNA of hepatitis B virus: an intermediate of covalently closed circular DNA formation. J. Virol. 81(22), 12472-12484 (2007).
49. Guo H, Mao R, Block TM, Guo JT: Production and function of the cytoplasmic deproteinized relaxed circular DNA of hepadnaviruses. J. Virol. 84(1), 387-396 (2010).
50. Mcallister R, Cortes-Ledesma F, Boregowda R, Caldecott K, Hu J: Characterizing the role of tyrosyl phosphodiesterase-2 in HBV cccDNA formation. Presented at: International Meeting on Molecular Biology of Hepatitis B Virus. Nankang, Taipei, Taiwan, October 9-13 2010.
51. Koeniger C, Nassal M, Beck J: Human tyrosyl-DNA-phosphodiesterase 2 can specifically remove polymerase from authentic hepadnaviral rc-DNA. Presented at: International Meeting on Molecular Biology of Hepatitis B Virus. Nankang, Taipei, Taiwan, October 9-13 2010.
52. Sohn JA, Litwin S, Seeger C: Mechanism for CCC DNA synthesis in hepadnaviruses. PLoS ONE 4(11), E8093 (2009).
53. Le Guerhier F, Pichoud C, Guerret S et al.: Characterization of the antiviral effect of 2',3'-dideoxy-2', 3'-didehydro-b-l-5- fluorocytidine in the duck hepatitis B virus infection model. Antimicrob. Agents Chemother. 44(1), 111-122 (2000). (Pubitemid 30010680)
54. Kock J, Baumert TF, Delaney WE, Blum HE, Von Weizsacker F: Inhibitory effect of adefovir and lamivudine on the initiation of hepatitis B virus infection in primary tupaia hepatocytes. Hepatology 38(6), 1410-1418 (2003). (Pubitemid 37466967)
55. Delmas J, Schorr O, Jamard C et al.: Inhibitory effect of adefovir on viral DNA synthesis and covalently closed circular DNA formation in duck hepatitis B virus-infected hepatocytes in vivo and in vitro. Antimicrob. Agents Chemother. 46(2), 425-433 (2002). (Pubitemid 34087191)
56. Kock J, Rosler C, Zhang JJ, Blum HE, Nassal M, Thoma C: Generation of covalently closed circular DNA of hepatitis B viruses via intracellular recycling is regulated in a virus specific manner. PLoS Pathog. 6(9), E1001082 (2010).
57. Lutgehetmann M, Volz T, Kopke A et al.: In vivo proliferation of hepadnavirus-infected hepatocytes induces loss of covalently closed circular DNA in mice. Hepatology 52(1), 16-24 (2010).
58. Bock CT, Schranz P, Schroder CH, Zentgraf H: Hepatitis B virus genome is organized into nucleosomes in the nucleus of the infected cell. Virus Genes 8(3), 215-229 (1994). (Pubitemid 24239779)
59. Newbold JE, Xin H, Tencza M et al.: The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minichromosomes. J. Virol. 69(6), 3350-3357 (1995).
60. Pollicino T, Belloni L, Raffa G et al.: Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones. Gastroenterology 130(3), 823-837 (2006). (Pubitemid 43374531)
61. Belloni L, Pollicino T, De Nicola F et al.: Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function. Proc. Natl Acad. Sci. USA 106(47), 19975-19979 (2009).
62. Vivekanandan P, Thomas D, Torbenson M: Methylation regulates hepatitis B viral protein expression. J. Infect. Dis. 199(9), 1286-1291 (2009).
63. Guo Y, Li Y, Mu S, Zhang J, Yan Z: Evidence that methylation of hepatitis B virus covalently closed circular DNA in liver tissues of patients with chronic hepatitis B modulates HBV replication. J. Med. Virol. 81(7), 1177-1183 (2009).
64. Quasdorff M, Protzer U: Control of hepatitis B virus at the level of transcription. J. Viral Hepat. 17(8), 527-536 (2010).
65. Quasdorff M, Hosel M, Odenthal M et al.: A concerted action of HNF4a and HNF1a links hepatitis B virus replication to hepatocyte differentiation. Cell Microbiol. 10(7), 1478-1490 (2008). (Pubitemid 351837268)
66. Hosel M, Quasdorff M, Wiegmann K et al.: Not interferon, but interleukin-6 controls early gene expression in hepatitis B virus infection. Hepatology 50(6), 1773-1782 (2009).
67. Ying C, Li Y, Leung CH, Robek MD, Cheng YC: Unique antiviral mechanism discovered in anti-hepatitis B virus research with a natural product analogue. Proc. Natl Acad. Sci. USA 104(20), 8526-8531 (2007). (Pubitemid 47175521)
68. Ott M, Thyagarajan SP, Gupta S: Phyllanthus amarus suppresses hepatitis B virus by interrupting interactions between HBV enhancer I and cellular transcription factors. Eur. J. Clin. Invest. 27(11), 908-915 (1997). (Pubitemid 27483524)
69. Hoeksema KA, Tyrrell DL: Inhibition of viral transcription using designed zinc finger proteins. Methods Mol. Biol. 649, 97-116 (2010).
70. Kim HJ, Yoo HS, Kim JC et al.: Antiviral effect of Curcuma longa Linn extract against hepatitis B virus replication. J. Ethnopharmacol. 124(2), 189-196 (2009).
71. Pang R, Tao JY, Zhang SL et al.: In vitro antiviral activity of lutein against hepatitis B virus. Phytother. Res. 24(11), 1627-1630 (2010).
72. Cui X, Inagaki Y, Xu H et al.: Antihepatitis B virus activities of cinobufacini and its active components bufalin and cinobufagin in HepG2.2.15 cells. Biol. Pharm. Bull. 33(10), 1728-1732 (2010).
73. Pang R, Tao J, Zhang S et al.: In vitro anti-hepatitis B virus effect of Hypericum perforatum L. J. Huazhong Univ. Sci. Technolog. Med. Sci. 30(1), 98-102 (2010).
74. Klein C, Bock CT, Wedemeyer H et al.: Inhibition of hepatitis B virus replication in vivo by nucleoside analogues and siRNA. Gastroenterology 125(1), 9-18 (2003). (Pubitemid 36799102)
75. Shlomai A, Shaul Y: Inhibition of hepatitis B virus expression and replication by RNA interference. Hepatology 37(4), 764-770 (2003). (Pubitemid 36397386)
76. Chen Y, Cheng G, Mahato RI: RNAi for treating hepatitis B viral infection. Pharm. Res. 25(1), 72-86 (2008).
77. Wilson R, Purcell D, Netter HJ, Revill PA: Does RNA interference provide new hope for control of chronic hepatitis B infection? Antivir. Ther. 14(7), 879-889 (2009).
78. Wang J, Feng SS, Wang S, Chen ZY: Evaluation of cationic nanoparticles of biodegradable copolymers as siRNA delivery system for hepatitis B treatment. Int. J. Pharm. 400(1-2), 194-200 (2010).
79. Teng X, Xu WZ, Hao ML et al.: Differential inhibition of lamivudine-resistant hepatitis B virus by allele-specific RNAi. J. Virol. Methods 168(1-2), 6-12 (2010).
80. Li Z, He ML, Yao H et al.: Inhibition of HBV replication and gene expression in vitro and in vivo with a single AAV vector delivering two shRNA molecules. BMB Rep. 42(1), 59-64 (2009).
81. Crowther C, Ely A, Hornby J et al.: Efficient inhibition of hepatitis B virus replication in vivo, using polyethylene glycol-modified adenovirus vectors. Hum. Gene Ther. 19(11), 1325-1331 (2008).
82. Xin XM, Li GQ, Guan XR et al.: Combination therapy of siRNAs mediates greater suppression on hepatitis B virus cccDNA in HepG2.2.15 cell. Hepatogastroenterology 55(88), 2178-2183 (2008).
83. Offensperger WB, Offensperger S, Walter E et al.: In vivo inhibition of duck hepatitis B virus replication and gene expression by phosphorothioate modified antisense oligodeoxynucleotides. EMBO J. 12(3), 1257-1262 (1993). (Pubitemid 23095875)
84. Robaczewska M, Guerret S, Remy JS et al.: Inhibition of hepadnaviral replication by polyethylenimine-based intravenous delivery of antisense phosphodiester oligodeoxynucleotides to the liver. Gene Ther. 8(11), 874-881 (2001). (Pubitemid 32577192)
85. Feng Y, Kong YY, Wang Y, Qi GR: Inhibition of hepatitis B virus by hammerhead ribozyme targeted to the poly(A) signal sequence in cultured cells. Biol. Chem. 382(4), 655-660 (2001). (Pubitemid 32472176)
86. Feng Y, Kong YY, Wang Y, Qi GR: Intracellular inhibition of the replication of hepatitis B virus by hammerhead ribozymes. J. Gastroenterol. Hepatol. 16(10), 1125-1130 (2001). (Pubitemid 32990108)
87. Nash KL, Alexander GJ, Lever AM: Inhibition of hepatitis B virus by lentiviral vector delivered antisense RNA and hammerhead ribozymes. J. Viral Hepat. 12(4), 346-356 (2005). (Pubitemid 40961473)
88. Li X, Kuang E, Dai W, Zhou B, Yang F: Efficient inhibition of hepatitis B virus replication by hammerhead ribozymes delivered by hepatitis delta virus. Virus Res. 114(1-2), 126-132 (2005). (Pubitemid 41586605)
89. Wang CX, Lu YQ, Qi P, Chen LH, Han JX: Efficient inhibition of hepatitis B virus replication by hepatitis delta virus ribozymes delivered by targeting retrovirus. Virol. J. 7, 61 (2010).
90. Gordien E, Rosmorduc O, Peltekian C, Garreau F, Brechot C, Kremsdorf D: Inhibition of hepatitis B virus replication by the interferon-inducible MxA protein. J. Virol. 75(6), 2684-2691 (2001). (Pubitemid 32185032)
91. Zlotnick A, Johnson JM, Wingfield PW, Stahl SJ, Endres D: A theoretical model successfully identifies features of hepatitis B virus capsid assembly. Biochemistry 38(44), 14644-14652 (1999).
92. Hirsch RC, Lavine JE, Chang LJ, Varmus HE, Ganem D: Polymerase gene products of hepatitis B viruses are required for genomic RNA packaging as wel as for reverse transcription. Nature 344(6266), 552-555 (1990).
93. Junker-Niepmann M, Bartenschlager R, Schaller H: A short cis-acting sequence is required for hepatitis B virus pregenome encapsidation and sufficient for packaging of foreign RNA. EMBO J. 9(10), 3389-3396 (1990).
94. Nassal M: The arginine-rich domain of the hepatitis B virus core protein is required for pregenome encapsidation and productive viral positive-strand DNA synthesis but not for virus assembly. J. Virol. 66(7), 4107-4116 (1992).
95. Knaus T, Nassal M: The encapsidation signal on the hepatitis B virus RNA pregenome forms a stem-loop structure that is critical for its function. Nucleic Acids Res. 21(17), 3967-3975 (1993). (Pubitemid 23258709)
96. Porterfield JZ, Dhason MS, Loeb DD, Nassal M, Stray SJ, Zlotnick A: Full-length hepatitis B virus core protein packages viral and heterologous RNA with similarly high levels of cooperativity. J. Virol. 84(14), 7174-7184 (2010).
97. King RW, Ladner SK, Miller TJ et al.: Inhibition of human hepatitis B virus replication by AT-61, a phenylpropenamide derivative, alone and in combination with (-) b-l-2',3'-dideoxy-3'-thiacytidine. Antimicrob. Agents Chemother. 42(12), 3179-3186 (1998). (Pubitemid 28553739)
98. Delaney WE, Edwards R, Colledge D et al.: Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro. Antimicrob. Agents Chemother. 46(9), 3057-3060 (2002).
99. Feld JJ, Colledge D, Sozzi V, Edwards R, Littlejohn M, Locarnini SA: The phenylpropenamide derivative AT-130 blocks HBV replication at the level of viral RNA packaging. Antiviral Res. 76(2), 168-177 (2007). (Pubitemid 47410321)
100. Xu WS, Zhao KK, Miao XH et al.: Effect of oxymatrine on the replication cycle of hepatitis B virus in vitro. World J. Gastroenterol. 16(16), 2028-2037 (2010).
101. Katen SP, Chirapu SR, Finn MG, Zlotnick A: Trapping of hepatitis B virus capsid assembly intermediates by phenylpropenamide assembly accelerators. ACS Chem. Biol. 5(12), 1125-1136 (2010).
102. Deres K, Schroder CH, Paessens A et al.: Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids. Science 299(5608), 893-896 (2003). (Pubitemid 36182448)
103. Bourne C, Lee S, Venkataiah B et al.: Small-molecule effectors of hepatitis B virus capsid assembly give insight into virus life cycle. J. Virol. 82(20), 10262-10270 (2008).
104. Wu GY, Zheng XJ, Yin CC et al.: Inhibition of hepatitis B virus replication by Bay 41-4109 and its association with nucleocapsid disassembly. J. Chemother. 20(4), 458-467 (2008).
105. Zhu X, Zhao G, Zhou X et al.: 2,4-diaryl- 4,6,7,8-tetrahydroquinazolin- 5(1H)-one derivatives as anti-HBV agents targeting at capsid assembly. Bioorg. Med. Chem. Lett. 20(1), 299-301 (2010).
106. Tomai E, Butz K, Lohrey C, Von Weizsacker F, Zentgraf H, Hoppe-Seyler F: Peptide aptamer-mediated inhibition of target proteins by sequestration into aggresomes. J. Biol. Chem. 281(30), 21345-21352 (2006). (Pubitemid 44115473)
107. Zlotnick A, Ceres P, Singh S, Johnson JM: A small molecule inhibits and misdirects assembly of hepatitis B virus capsids. J. Virol. 76(10), 4848-4854 (2002). (Pubitemid 34441690)
108. Schultz U, Summers J, Staeheli P, Chisari FV: Elimination of duck hepatitis B virus RNA-containing capsids in duck interferon-a-treated hepatocytes. J. Virol. 73(7), 5459-5465 (1999). (Pubitemid 29274828)
109. Biermer M, Puro R, Schneider RJ: Tumor necrosis factor alpha inhibition of hepatitis B virus replication involves disruption of capsid Integrity through activation of NF-kB. J. Virol. 77(7), 4033-4042 (2003). (Pubitemid 36350944)
110. Zoulim F, Locarnini S: Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 137(5), 1593-1608, E1-E2 (2009).
111. Mason WS, Aldrich C, Summers J, Taylor JM: Asymmetric replication of duck hepatitis B virus DNA in liver cells: free minus-strand DNA. Proc. Natl Acad. Sci. USA 79(13), 3997-4001 (1982).
112. Weiser B, Ganem D, Seeger C, Varmus HE: Closed circular viral DNA and asymmetrical heterogeneous forms in livers from animals infected with ground squirrel hepatitis virus. J. Virol. 48(1), 1-9 (1983). (Pubitemid 13006716)
113. Roseman AM, Berriman JA, Wynne SA, Butler PJ, Crowther RA: A structural model for maturation of the hepatitis B virus core. Proc. Natl Acad. Sci. USA 102(44), 15821-15826 (2005). (Pubitemid 41552826)
114. Perlman DH, Berg EA, O'Connor PB, Costello CE, Hu J: Reverse transcription-associated dephosphorylation of hepadnavirus nucleocapsids. Proc. Natl Acad. Sci. USA 102(25), 9020-9025 (2005). (Pubitemid 40881071)
115. Wittkop L, Schwarz A, Cassany A et al.: Inhibition of protein kinase C phosphorylation of hepatitis B virus capsids inhibits virion formation and causes intracellular capsid accumulation. Cell Microbiol. 12(7), 962-975 (2010).
116. Bruss V, Vieluf K: Functions of the internal pre-S domain of the large surface protein in hepatitis B virus particle morphogenesis. J. Virol. 69(11), 6652-6657 (1995).
117. Summers J, Smith PM, Horwich AL: Hepadnavirus envelope proteins regulate covalently closed circular DNA amplification. J. Virol. 64(6), 2819-2824 (1990). (Pubitemid 20171271)
118. Bottcher B, Tsuji N, Takahashi H et al.: Peptides that block hepatitis B virus assembly: analysis by cryomicroscopy, mutagenesis and transfection. EMBO J. 17(23), 6839-6845 (1998). (Pubitemid 28550277)
119. Patient R, Hourioux C, Roingeard P: Morphogenesis of hepatitis B virus and its subviral envelope particles. Cell Microbiol. 11(11), 1561-1570 (2009).
120. Block TM, Lu X, Mehta AS et al.: Treatment of chronic hepadnavirus infection in a woodchuck animal model with an inhibitor of protein folding and trafficking. Nat. Med. 4(5), 610-614 (1998). (Pubitemid 28237362)
121. Simsek E, Lu X, Ouzounov S, Block TM, Mehta AS: a-Glucosidase inhibitors have a prolonged antiviral effect against hepatitis B virus through the sustained inhibition of the large and middle envelope glycoproteins. Antivir. Chem. Chemother. 17(5), 259-267 (2006). (Pubitemid 44901470)
122. Lazar C, Durantel D, Macovei A et al.: Treatment of hepatitis B virus-infected cells with alpha-glucosidase inhibitors results in production of virions with altered molecular composition and infectivity. Antiviral Res. 76(1), 30-37 (2007). (Pubitemid 47189679)
123. Serruys B, Van Houtte F, Verbrugghe P, Leroux-Roels G, Vanlandschoot P: Llamaderived single-domain intrabodies inhibit secretion of hepatitis B virions in mice. Hepatology 49(1), 39-49 (2009).
124. Neumann AU, Phillips S, Levine I et al.: Novel mechanism of antibodies to hepatitis B virus in blocking viral particle release from cells. Hepatology 52(3), 875-885 (2010).
125. Bremer CM, Bung C, Kott N, Hardt M, Glebe D: Hepatitis B virus infection is dependent on cholesterol in the viral envelope. Cell Microbiol. 11(2), 249-260 (2009).
126. Pollock S, Nichita NB, Bohmer A, Radulescu C, Dwek RA, Zitzmann N: Polyunsaturated liposomes are antiviral against hepatitis B and C viruses and HIV by decreasing cholesterol levels in infected cells. Proc. Natl Acad. Sci. USA 107(40), 17176-17181 (2010).
127. Dougherty AM, Guo H, Westby G et al.: A substituted tetrahydro-tetrazolo- pyrimidine is a specific and novel inhibitor of hepatitis B virus surface antigen secretion. Antimicrob. Agents Chemother. 51(12), 4427-4437 (2007). (Pubitemid 350209899)
128. Huang KL, Lai YK, Lin CC, Chang JM: Involvement of GRP78 in inhibition of HBV secretion by Boehmeria nivea extract in human HepG2 2.2.15 cells. J. Viral Hepat. 16(5), 367-375 (2009).
129. Wang HP, Rogler CE: Topoisomerase I-mediated integration of hepadnavirus DNA in vitro. J. Virol. 65(5), 2381-2392 (1991).
130. Chemin I, Zoulim F: Hepatitis B virus induced hepatocellular carcinoma. Cancer Lett. 286(1), 52-59 (2009).
131. Liaw YF: Hepatitis B virus replication and liver disease progression: the impact of antiviral therapy. Antivir. Ther. 11(6), 669-679 (2006).
132. Hildt E, Munz B, Saher G, Reifenberg K, Hofschneider PH: The PreS2 activator MHBs(t) of hepatitis B virus activates c-raf-1/Erk2 signaling in transgenic mice. EMBO J. 21(4), 525-535 (2002). (Pubitemid 34174034)
133. Hsieh YH, Su IJ, Wang HC et al.: Pre-S mutant surface antigens in chronic hepatitis B virus infection induce oxidative stress and DNA damage. Carcinogenesis 25(10), 2023-2032 (2004).
134. Benhenda S, Cougot D, Buendia MA, Neuveut C: Hepatitis B virus X protein molecular functions and its role in virus life cycle and pathogenesis. Adv. Cancer Res. 103, 75-109 (2009).
135. Wieland S, Thimme R, Purcell RH, Chisari FV: Genomic analysis of the host response to hepatitis B virus infection. Proc. Natl Acad. Sci. USA 101(17), 6669-6674 (2004). (Pubitemid 38586032)
136. Wieland SF, Chisari FV: Stealth and cunning: hepatitis B and hepatitis C viruses. J. Virol. 79(15), 9369-9380 (2005). (Pubitemid 41022281)
137. Lucifora J, Durantel D, Testoni B, Hantz O, Levrero M, Zoulim F: Control of hepatitis B virus replication by innate response of HepaRG cells. Hepatology 51(1), 63-72 (2010).
138. Ait-Goughoute M, Lucifora J, Zoulim F, Durantel D: Innate antiviral immune response to hepatitis B virus. Viruses 2, 1394-1410 (2010).
139. Nassal M: Hepatitis B viruses: reverse transcription a different way. Virus Res. 134(1-2), 235-249 (2008).
140. Lambert C, Doring T, Prange R: Hepatitis B virus maturation is sensitive to functional inhibition of ESCRT-III, Vps4, and g2- adaptin. J. Virol. 81(17), 9050-9060 (2007). (Pubitemid 47311448)
141. Rehermann B, Nascimbeni M: Immunology of hepatitis B virus and hepatitis C virus infection. Nat. Rev. Immunol. 5(3), 215-229 (2005). (Pubitemid 40364823)
142. Michel ML, Tiollais P: Hepatitis B vaccines: protective efficacy and therapeutic potential. Pathol. Biol. (Paris) 58(4), 288-295 (2010).
143. Protzer U, Abken H: Can engineered 'designer' T cells outsmart chronic hepatitis B? Hepat. Res. Treat. 2010, 901216 (2010).
144. De Clercq E: Strategies in the design of antiviral drugs. Nat. Rev. Drug Discov. 1(1), 13-25 (2002). (Pubitemid 37361400)
145. Vincent IE, Lucifora J, Durantel D et al.: Inhibitory effect of the combination of CpG-induced cytokines with lamivudine against hepatitis B virus replication in vitro. Antivir. Ther. 14(1), 131-135 (2009).